The legal and public health response to novel psychoactive drugs

This collection of papers addresses the issue of the 'legal highs' market, one which only a few years ago was regarded as an area of limited significance. Things change rapidly however, and today the question of how to respond to the challenges posed by the emergence of new drugs has become one of major international concern. The papers in this virtual issue highlight the need for a very different regulatory regime to address the challenge presented by a plethora of new psychoactive substances appearing on the market. Read the relating Editorial.

All articles in the virtual issue are available FREE to download until 30th September 2013.

Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings

Maren Hermanns-Clausen, Stefan Kneisel, Bela Szabo and Volker Auwärter, Addiction 108:3 534-44

Controlling new drugs under marketing regulations

Brendan Hughes and Adam R. Winstock, Addiction 107:11 1894-1899

Against Excess

Krzysztof Krajewski, Addiction 107:11 1900-1901

New Zealand to establish fit for purpose regulation for new psychoactive substances

Janie Sheridan, Bruce Atmore and Bruce Russell, Addiction 107:11 1901-1902

The dangerous charms of the unknown

Peter Reuter, Addiction 107:11 1902-1903

Supply always comes on the heels of demand: what effects to do control strategies have on drug users themselves?

Tom P. Freeman and H. Valerie Curran, Addiction 107:11, 1903-1905

No quick fix for legal highs

Jeremy Parsons, Addiction 107:11 2053–2054

Cognitive and subjective effects of mephedrone and factors influencing use of a new "legal high"

Tom P. Freeman, Celia J. A. Morgan, James Vaughn-Jones, Nahida Hussain, Kash Karimi and H. Valerie Curran, Addiction 107:4 792-800

Scheduling of newly emerging drugs: a critical review of decisions over 40 years

Carolyn Coulson and Jonathan P. Caulkins, Addiction 107:4 766-773

Optimizing drug scheduling

Mark A. R, Kleiman, Addiction 107:4 774-775

Mephedrone: use, subjective effects and health risks

Adam Winstock, Luke Mitcheson, John Ramsey, Susannah Davies, Malgorzata Puchnarewicz and John Marsden, Addiction 106:11 1991-1996

Mephedrone: new kid for the chop?

Adam R. Winstock1, Luke R. Mitcheson, Paolo Deluca1, Zoe Davey, Ornella Corazza and Fabrizio Schifano, Addiction 106:1 154-161



AN ANTI-INFLAMMATORY AS A RECREATIONAL DRUG IN BRAZIL

EMERITA S. OPALEYE, ZILA M. SANCHEZ, YONE G. MOURA, DANILO P. LOCATELLI and ANA R. NOTO, Addiction 106:1 225

Legal highs and the challenges for policy makers

Adam R. Winstock and John D. Ramsey, Addiction 105:10 1685-1687

Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals

Susanna Avery-Palmer, Addiction 105:10 1859-1860

How globalization and market innovation challenge how we think about and respond to drug use: 'Spice' a case study

Paul Griffiths, Roumen Sedefov, Ana Gallegos and Dominique Lopez, Addiction 105:6 951-953

Dangers of banning spice and the synthetic cannabinoid agents

Richard Hammersley, Addiction 105:2 373



